text: drug treatments. Their aim was to identify compounds that block the clumping, or aggregation, of alpha- 
  synuclein (the protein that characterises Parkinson's disease). They were able to speed up the initial 
  screening process ten-fold and reduce the cost by a thousand-fold.[136][137] 